GlassScriptPhysician profile
Eugene V Kramolowsky
NPI 1558324475
$14,654.05
in general payments reported to CMS, 2019-2025
33 companies · $58.23 in 2025
The $58.23 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $460 · 2021: $1,329 · 2022: $443 · 2023: $363 · 2024: $215 · 2025: $58.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $11,872.28 | 2019-2021 | |
| Janssen Biotech, INC. | $641.70 | 2019-2023 | Erleada |
| Dendreon Pharmaceuticals LLC | $443.59 | 2019-2024 | Provenge |
| Abbvie INC. | $265.12 | 2021-2025 | |
| Blue Earth Diagnostics | $212.52 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.72 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $140.29 | 2019-2021 | |
| Antares Pharma, INC. | $100.41 | 2019-2022 | |
| Amgen INC. | $96.91 | 2019-2022 | |
| Rochester Medical Corporation | $90.10 | 2019-2021 | |
| Urogen Pharma, INC. | $76.70 | 2021-2023 | Jelmyto |
| Pfizer INC. | $72.67 | 2019-2021 | |
| Astellas Pharma US INC | $63.73 | 2019-2020 | |
| Neotract INC. | $56.23 | 2020 | |
| Ambu INC. | $49.52 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $38.12 | 2023-2024 | Pylarify |
| Astrazeneca Pharmaceuticals LP | $37.52 | 2021 | |
| Urovant Sciences INC | $37.17 | 2022 | |
| Ferring Pharmaceuticals INC. | $25.34 | 2024 | Adstiladrin |
| Tolmar, INC. | $24.06 | 2023 | |
| Merck Sharp & Dohme LLC | $23.06 | 2021 | |
| Teleflex LLC | $22.80 | 2021 | |
| Sumitomo Pharma America, INC. | $21.94 | 2024 | Gemtesa |
| Genzyme Corporation | $21.83 | 2023 | |
| Sun Pharmaceutical Industries INC. | $14.04 | 2019 | |
| Axonics, INC. | $12.51 | 2022 | |
| Clovis Oncology, INC. | $12.17 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Kramolowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.